A practical reference on 脂肪酸酰化: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
The first atomic bomb test, codenamed "Trinity "and detonated on July 16, 1945, near Alamogordo, New Mexico, used plutonium as its fissile material. The implosion design of "Gadget", as the Trinity device was codenamed, used conventional explosive lenses to compress a sphere of plutonium into a supercritical mass, which was simultaneously showered with neutrons from "Urchin", an initiator made of polonium and beryllium (neutron source: (α, n) reaction). Together, these ensured a runaway chain reaction and explosion. The weapon weighed over 4 tonnes, though it had just 6 kg of plutonium. About 20% of the plutonium in the Trinity weapon, fissioned; releasing an energy equivalent to about 20,000 tons of TNT. An identical design was used in "Fat Man", dropped on Nagasaki, Japan, on August 9, 1945, killing 35,000–40,000 people and destroying 68%–80% of war production at Nagasaki. Only after the announcement of the first atomic bombs was the existence and name of plutonium made known to the public by the Manhattan Project's Smyth Report.
Within the immune system, prolactin acts to promote lymphocyte differentiation, proliferation, and function through the activation of protein kinase C signaling pathway. Prolactin has immunomodulatory and anti-inflammatory effects within the immune system, contributing to immune system maintenance. Stress also acutely stimulates prolactin production, as dopamine (a prolactin inhibitor) levels are reduced under stress, the pituitary gland is in turn expressed more leading to higher prolactin levels.
== Early career and provincial forestry == Recruited into the Imperial Forest Service during the early 1930s through a competitive, merit-based process, Singh began his career as a forest officer in the Bombay Presidency. He subsequently undertook provincial assignments in regions such as Punjab, where he managed resources amid challenges like habitat loss and poaching. He focused on combating overexploitation through regulated hunting, enhanced patrol systems, and community engagement. In 1957, he detailed his strategies for wildlife preservation and sustained timber yields in an article published in The Indian Forester. For his service in forest administration prior to Indian independence, the British Government appointed him a Member of the Order of the British Empire (MBE). On May 1, 1960, Singh was appointed Chief Conservator of Forests for Gujarat State, where he prioritized administrative efficiency and insulated operations from ad hoc political directives during a period of post-independence consolidation.
As the leader of the Cure Alzheimer's Fund's Alzheimer's Genome Project, Tanzi several other AD genes, most notably, CD33, reported in 2008 with Lars Bertram, in the American Journal of Human Genetics. In that study, Tanzi reported the first family-based genome-wide association study of AD, which most notably to the identification of the first innate immune microglial AD gene, CD33, which encodes a cell-surface receptor on monocytes and microglia. In 2013, Tanzi and Dr. Ana Griciuc first reported in Neuron that increased expression of CD33 in microglial cells in AD brain and showed that a protective CD33 gene variant was associated with reductions in CD33 expression and Abeta levels in AD brain. Importantly, they showed CD33 inhibits microglial phagocytosis and clearance of Abeta and induces pro-inflammatory cytokine release leading to neuroinflammation. They also elucidated the molecular mechanism by which sialic acid binds to CD33 to induce neuroinflammation. In a follow-up study published in Neuron in 2019, Tanzi and Griciuc compared the neuroinflammatory effects of the CD33 gene to another AD-associated innate immune gene, TREM2. Knockout of CD33 in AD mice attenuated amyloid-beta pathology and improved cognition while knockout of TREM2 led to opposite effects. They then showed that TREM2 functions downstream of CD33 and that crosstalk between CD33 and TREM2 involves the neuroinflammation-related IL-1beta/IL-1RN axis cluster.
== Amyloid toxicity == The reasons why amyloid cause diseases are unclear. In some cases, the deposits physically disrupt tissue architecture, suggesting disruption of function by some bulk process. An emerging consensus implicates prefibrillar intermediates, rather than mature amyloid fibers, in causing cell death, particularly in neurodegenerative diseases. The fibrils are, however, far from innocuous, as they keep the protein homeostasis network engaged, release oligomers, cause the formation of toxic oligomers via secondary nucleation, grow indefinitely spreading from district to district and, in some cases, may be toxic themselves. Calcium dysregulation has been observed to occur early in cells exposed to protein oligomers. These small aggregates can form ion channels through lipid bilayer membranes and activate NMDA and AMPA receptors. Channel formation has been hypothesized to account for calcium dysregulation and mitochondrial dysfunction by allowing indiscriminate leakage of ions across cell membranes. Studies have shown that amyloid deposition is associated with mitochondrial dysfunction and a resulting generation of reactive oxygen species (ROS), which can initiate a signalling pathway leading to apoptosis. There are reports that indicate amyloid polymers (such as those of huntingtin, associated with Huntington's disease) can induce the polymerization of essential amyloidogenic proteins, which should be deleterious to cells. Also, interaction partners of these essential proteins can also be sequestered. All these mechanisms of toxicity are likely to play a role.
Sources: en.wikipedia.org
Bones are surrounded by a membrane known as the periosteum (Greek περῐ́ (perí), around; Greek ὀστέον (ostéon), bone), and comprise multiple layers, depending on the type of bone, including yellow and red bone marrow, spongy bone, and the endosteum. There are five general classifications of bones: Long bones are characterized by a shaft known as the diaphysis, which is much longer than its width, and an epiphysis (Greek ἐπι- (epi-) upon, outside, over), a rounded head at each end of the shaft, connected to the diaphysis by the epiphyseal plate. They are made up mostly of compact bone, with lesser amounts of marrow, located within the medullary cavity, and areas of spongy, cancellous bone at the ends of the bones. Short bones are roughly cube-shaped, and have only a thin layer of compact bone surrounding a spongy interior. Short bones provide stability and support as well as some limited motion. Flat bones are thin and generally curved, with two parallel layers of compact bone sandwiching a layer of spongy bone. Sesamoid bones are bones embedded in tendons. Since they act to hold the tendon further away from the joint, the angle of the tendon is increased and thus the leverage of the muscle is increased. Irregular bones do not fit into the above categories. They consist of thin layers of compact bone surrounding a spongy interior. As implied by the name, their shapes are irregular and complicated. Often this irregular shape is due to their many centers of ossification or because they contain bony sinuses.
==== Music ==== MDMA and ecstasy have featured in a number of songs, including Miley Cyrus's "We Can't Stop", Jay-Z and Alicia Keys' "Empire State of Mind", Fujiya & Miyagi's "Seratonin Rushes", Soulwax's "E Talking", Nonpoint's "Double Stacked", Green Velvet's "La La Land", Primal Scream's "Don't Fight It, Feel It", The Streets' "Blinded by the Lights", The Shamen's "Ebeneezer Goode", Missy Elliott's "4 My People", Pulp's "Sorted for E's & Wizz" and Hot Chip's "Over and Over".
This is a list of molecules that have been detected in the interstellar medium and circumstellar envelopes, grouped by the number of component atoms. The chemical formula is listed for each detected compound, along with any ionized form that has also been observed.
=== Masculinity and social bonds === Comics scholar Jeffrey K. Johnson argues that Wolverine incarnates cultural values of the Reagan era, emphasizing individualism and retributive justice. Similarly, Neil Shyminsky claims that "Wolverine's appeal is grounded in nostalgia for a morally absolute brand of dangerous masculinity." Gerri Mahn, however, draws attention to the theme of vulnerability in Wolverine's stories, particularly the Fatal Attractions story in which Wolverine is gravely injured by Magneto and loses his adamantium bone lacing. Mahn claims that this experience of recuperation from injury presented an opportunity for Wolverine to redefine his gender identity, establishing more caring bonds with others. Christopher Michael Roman connects this moment to the continual theme of Wolverine stories in which he cares for a younger person, usually a young woman. While it might seem that Wolverine is learning to be a surrogate father, Roman claims that the kinship bonds are more complicated than a father-child relationship. In his relationship with Kitty Pryde, Roman argues that Wolverine actually teaches her to redefine herself without relying on a father figure, and that their bond is grounded in shared vulnerability. He also draws attention to Wolverine's role as a mentor to other characters like Colossus, Jubilee, Armor, and Quentin Quire.
== Overdose == Doses of methenamine much higher than usual have been clinically studied and found to produce significant toxicity. More specifically, doses of 8 g per day (4–8-fold usual doses) for 3 to 4 weeks resulted in bladder irritation, painful and frequent urination, albuminuria (albumin in urine), crystalluria (crystals in urine), and hematuria (blood in urine). Some of these side effects are thought to be due to high levels of formaldehyde in the bladder and consequent irritation. Doses of methenamine of up to 10 to 20 g/day have also been studied and found to be tolerable without major toxicity. When methenamine was first introduced in the late 1800s and early 1900s, doses of 15 to 30 g per day were commonly employed and doses of up to 60 to 180 g per day were tried in some cases. Toxic effects of such high doses included urinary tract and bladder irritation, frequent urination, strangury, and hematuria. Animal studies employing double the modern human dosage of methenamine for 6 to 12 months found no adverse effects.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.